Posters
Results of selective laser trabeculoplasty treatment for patients with open-angle glaucoma during a 2 year period
Poster Details
First Author: M.Ponte-Davila PERU
Co Author(s): J. Izquierdo Villavicencio F. Quezada Baltodano I. Ramirez Jimenez A. Gonz�Ã�¡lez M�Ã�©ndez B. Rubio Lastra
Abstract Details
Purpose:
To describe the results of selective laser trabeculoplasty for patients with open-angle glaucoma during a 2-year period.
Setting:
Research Department, Oftalmosalud Eye Institute, Lima-Peru, Av. Javier Prado Este 1142, San Isidro, Lima, Peru
Methods:
A descriptive, retrospective, and longitudinal study was conducted among 40 eyes of 20 patients who underwent selective laser trabeculoplasty from 2012 to 2015 and received topical antiglaucoma medication. The following variables were measured: uncorrected visual acuity, best-corrected visual acuity, and intraocular pressure and drugs before treatment and during monitoring controls after 1 day, 7 days, 1 month, 3 months, 6 months, 12 months, and 24 months.
Results:
No significant differences were identified between uncorrected visual acuity preoperatively and at 1 year (p=0.091) or between preoperative uncorrected visual acuity preoperatively and at 2 years (p=0.827). Best-corrected visual acuity preoperatively and at 1 year showed no statistical significance (p=0.125); however, best-corrected visual acuity preoperatively and at 2 years had statistical significance (p=0.007). Mean �Â�± standard deviation of preoperative intraocular pressure at 2 years had decreased from 17.28�Â�±5.7 to 13.05�Â�±2.4 mm Hg (statistically significant; p=0.00) and the success rate was 75%. Although the mean �Â�± standard deviation of preoperative for drug use at 2 years decreased from 1.90�Â�±1.1 to 1.65�Â�±1.3, no significant difference (p=0.058) was identified. No complications were identified.
Conclusions:
Selective laser trabeculoplasty is an effective and safe treatment that reduces intraocular pressure as well as the number of drugs required by patients with open-angle glaucoma.
Financial Disclosure:
NONE
